XGN

Exagen Inc

XGN, USA

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

https://www.exagen.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
XGN
stock
XGN

Trading the Move, Not the Narrative: (XGN) Edition news.stocktradersdaily.com

Read more →
XGN
stock
XGN

The Market Doesn't Like What It Sees From Exagen Inc.'s (NASDAQ:XGN) Revenues Yet As Shares Tumble 27% simplywall.st

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$15.4286

Analyst Picks

Strong Buy

5

Buy

0

Hold

1

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

8.99

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-39.07 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-11.28 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

15.48 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

2.46

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 48.14% of the total shares of Exagen Inc

1.

RTW INVESTMENTS, LLC

(7.7118%)

since

2025/06/30

2.

The Toronto-Dominion Bank

(3.8689%)

since

2025/06/30

3.

Balyasny Asset Management LLC

(3.2667%)

since

2025/06/30

4.

Vanguard Group Inc

(3.0978%)

since

2025/06/30

5.

Silvercrest Asset Management Group LLC

(2.4167%)

since

2025/06/30

6.

Morgan Stanley - Brokerage Accounts

(2.386%)

since

2025/06/30

7.

Driehaus Capital Management LLC

(2.1856%)

since

2025/06/30

8.

UBS Group AG

(2.0279%)

since

2025/06/30

9.

Vanguard Total Stock Mkt Idx Inv

(1.9864%)

since

2025/07/31

10.

Wexford Capital LP

(1.8922%)

since

2025/06/30

11.

Calamos Timpani Small Cap Growth I

(1.8823%)

since

2025/07/31

12.

Timpani Small Cap Growth Equity

(1.684%)

since

2025/06/30

13.

Kennedy Capital Management Inc

(1.4121%)

since

2025/06/30

14.

Kennedy Micro Cap Opportunities

(1.4121%)

since

2025/06/30

15.

Perkins Capital Management Inc

(1.0537%)

since

2025/06/30

16.

Acadian Asset Management LLC

(1.0026%)

since

2025/06/30

17.

FourWorld Capital Management LLC

(0.9477%)

since

2025/06/30

18.

Manatuck Hill Partners LLC

(0.7953%)

since

2025/06/30

19.

Pleiades Small Cap Equity A

(0.7444%)

since

2025/06/30

20.

Silvercrest U.S. Small Cap Growth

(0.696%)

since

2025/06/30

21.

Geode Capital Management, LLC

(0.6657%)

since

2025/06/30

22.

Vanguard Institutional Extnd Mkt Idx Tr

(0.6624%)

since

2025/07/31

23.

Point72 Asset Management, L.P.

(0.6198%)

since

2025/06/30

24.

Mink Brook Asset Management LLC

(0.5908%)

since

2025/06/30

25.

IMC US Ultra Micro Cap

(0.4745%)

since

2025/07/31

27.

Ameriprise Financial Inc

(0.4315%)

since

2025/06/30

28.

Huntleigh Advisors Inc

(0.3993%)

since

2025/06/30

29.

Fidelity Extended Market Index

(0.313%)

since

2025/07/31

30.

Russell Inv US Small Cap Equity Y

(0.1587%)

since

2025/07/31

31.

North Square Kennedy MicroCap I

(0.117%)

since

2025/06/30

32.

Russell Inv Small Cap Fund F

(0.1114%)

since

2025/07/31

33.

iShares Micro-Cap ETF

(0.1078%)

since

2025/08/31

34.

Bridgeway Ultra-Small Company Market

(0.1027%)

since

2025/06/30

35.

Fidelity Total Market Index

(0.0992%)

since

2025/07/31

36.

Extended Equity Market Fund K

(0.0881%)

since

2025/06/30

37.

Fidelity Series Total Market Index

(0.0833%)

since

2025/07/31

38.

Perkins Discovery

(0.075%)

since

2025/06/30

39.

Spartan Extended Market Index Pool F

(0.0718%)

since

2025/07/31

40.

Fidelity Nasdaq Composite Index

(0.0545%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.1786

Latest Release

Date

2025-09-30

EPS Actual

-0.31

EPS Estimate

-0.16

EPS Difference

-0.15

Surprise Percent

-93.75%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(2.5)
Momentum
Moderate Momentum(4.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(3)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.